U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07078695) titled 'A Trial of SHR-1139 in Healthy Volunteers' on July 13.
Brief Summary: The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers
Study Start Date: Aug. 26
Study Type: INTERVENTIONAL
Condition:
Psoriasis
Intervention:
DRUG: SHR-1139 Injection
Single dose of SHR-1139 given subcutaneously (dose level 1 )
DRUG: SHR-1139 Injection
Single dose of SHR-1139 given subcutaneously (dose level 2 )
DRUG: SHR-1139 Injection
Single dose of SHR-1139 given intravenously (dose level 3)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Atridia Pty Ltd.
Disclaimer: Curated...